Featured Image: Downtown San Diego skyline water reflection midnight. Courtesy: © 2010 – 2018 Fotolia. Used with permission.

During the 2018 World ADC Congress, held in San Diego, November 12 – 15, 2018, PharmaMara presented a new Antibody-drug Conjugate or ADC called MI180021. The investigational agent combines trastuzumab with the marine molecule PM160057, a new family of molecules specifically designed as new “payloads.”

PharmaMar’s poster was selected as one of the top five for an oral presentation
during the Congress.[1]

This ADC has shown potent and highly selective activity in tumor cells that
overexpress HER2, as found in certain breast, gastric and pancreas cancers, among
others.

PM160057 belongs to a new family of molecules of marine origin that kill tumor cells by binding to DNA

Advertisement #3
 

New chemical structure
This family of new chemical structures with novel mechanisms of action offer the opportunity to develop a new generation of ADCs

This discovery reinforces the strategy of PharmaMar’s unit dedicated to obtaining compounds for the use of active agents in ADCs. This research has already led to the licensing of the first family of active molecules to Seattle Genetics, world leader in ADCs, for which PharmaMar received an initial payment of US $ 5 million.

“MI180021 has a high selectivity against cancer cells that overexpress HER2 receptor, providing a new opportunity to treat patients with these types of cancers, such as breast, gastric and pancreatic,” noted Carmen Cuevas, Director of Research and Development at PharmaMar.

Reference
[1] MI180021: A Novel ADC with a New Marine DNA Binder Payload” – Carman Cuevas, Director, Research & Development (4:30pm Tuesday, November 13, 2018)